Gastroenterology
Latest news
363 articles · 20 / page
Higher Early IV Fluid Rates Tied to More SIRS but Lower BUN Rise in Acute Pancreatitis: Findings From an International Cohort Presented at ACG 2025
An international prospective cohort found that higher early IV fluid rates were associated with lower odds of BUN rise but higher odds of new or persistent SIRS at 6 and 24 hours after presentation, highlighting confounding issues and the n
Recent Advances in Alcohol Metabolism: from the Gut to the Brain
This article reviews the latest findings on human alcohol metabolism, covering evolutionary biology, systemic and brain-specific pathways, genetic and physiological modulators, clinical implications of metabolic variability, and emerging th
Gastrointestinal Burden in CHARGE Syndrome: High Prevalence of Constipation, Age-Related Patterns, and Quality‑of‑Life Impact
In a cohort of 50 individuals with CHARGE syndrome, GI problems affected 64% and constipation 48%, with constipation associated with lower PedsQL GI scores and greater comorbidity; younger patients had more diverse GI issues while older pat
Expanding Donor Pools: Outcomes of Liver Transplantation Using Grafts from Medical Assistance in Dying Donors in Canada
This Canadian multicenter study evaluates liver transplant outcomes using grafts from donation after medical assistance in dying donors, showing comparable survival and complication rates to standard donors and increasing transplant activit
Advances in Gastrointestinal Cancer Therapeutics: Insights from NICHE-2, FOxTROT, Telisotuzumab Adizutecan, and Emerging Trials
This article reviews pivotal updates in gastrointestinal oncology from recent trials, emphasizing superior neoadjuvant immunotherapy in mismatch repair–deficient colorectal cancer, promising antibody-drug conjugates, and challenges in novel
Enhancing Prognostication in Chronic Liver Disease: The Role of Liver Corrected T1 and Magnetic Resonance Elastography in Real-World Clinical Practice
This study highlights the complementary utility of liver corrected T1 (cT1) and magnetic resonance elastography (MRE) for predicting chronic liver disease progression, emphasizing the critical prognostic role of disease activity beyond fibr
Elafibranor Shows Promise as a Safe and Effective Therapy for Primary Sclerosing Cholangitis: Insights from the Phase II ELMWOOD Trial
The phase II ELMWOOD trial demonstrates that elafibranor, a dual PPAR-α/δ agonist, is well tolerated and significantly improves biochemical markers in patients with primary sclerosing cholangitis over 12 weeks, warranting further investigat
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study
The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.
Plant-Based Foods and Their Impact on Metabolic Health and Liver Function in Adults with MASLD and Comorbidities: A Systematic Review
This systematic review evaluates the effects of specific plant-based foods on metabolic and hepatic outcomes in adults with MASLD and related comorbidities. Findings reveal selective benefits of plant-based dietary components on liver healt
Time-Restricted Eating as a Promising Approach for Metabolic Dysfunction-Associated Steatotic Liver Disease: Evidence from a Randomized Controlled Trial
A 16-week RCT demonstrates that time-restricted eating significantly reduces hepatic steatosis in MASLD, offering comparable metabolic benefits to calorie restriction without adverse events.
Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival
This comprehensive analysis reveals that progression-free survival moderately correlates with overall survival in advanced biliary tract cancer, while objective response and disease control rates show poor correlation, underscoring the need
Rifaximin’s Role in Severe Cirrhosis with Ascites: Insights from a Randomized Controlled Trial
A randomized trial showed rifaximin does not improve 12-month survival or reduce complications in severe cirrhosis with ascites, but better adherence may decrease liver-related events.
Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications
The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding risk.
Rivaroxaban in Cirrhosis: A Promising Strategy to Prevent Portal Hypertension Complications
The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding risk.
Patient-Derived Liver Organoids: A Breakthrough for Precision Modeling and Treatment of Alcohol-Related Liver Disease
Patient-derived liver organoids from needle biopsies replicate liver epithelial diversity and disease stage features, enabling personalized modeling and therapeutic testing in alcohol-related liver disease.
Targeting Xanthine Oxidoreductase: A New Frontier to Overcome EGFR TKI Resistance in Intrahepatic Cholangiocarcinoma
Xanthine oxidoreductase (XOR) drives resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma by stabilizing EGFR and enhancing DNA repair. Targeting XOR sensitizes tumors to EGFR TKIs and suppresses cancer progressi
Proteogenomic Insights into Personalized Adjuvant Chemotherapy for Extrahepatic Cholangiocarcinoma
Comprehensive proteogenomic profiling in resected extrahepatic cholangiocarcinoma reveals predictive biomarkers for tailoring adjuvant chemotherapy, offering a precision medicine approach to improve patient outcomes.
Innovative TCR T-Cell Therapy Shows Promise in Advanced Hepatocellular and Gastric Hepatoid Carcinoma
A phase I trial reveals that ADP-A2AFP TCR T-cell therapy, targeting AFP-expressing advanced hepatocellular carcinoma and gastric hepatoid carcinoma, is safe and exhibits early antitumor activity in patients refractory to conventional treat
Unraveling Non-Acute Decompensation in Cirrhosis: A Distinct Clinical and Pathophysiological Entity with Prognostic Implications
Non-acute decompensation of cirrhosis (NAD) represents a distinct clinical state characterized by elevated cell death markers and moderate prognosis. Identifying predictors such as ascites severity and biomarkers Gasdermin-D and RIPK3 may g
RIPK3 as a Prognostic Biomarker in Acute Decompensation of Cirrhosis: Advancing Risk Stratification and Therapeutic Targeting
RIPK3-associated necroptosis critically drives organ failure and mortality in acute decompensation and ACLF, with its plasma levels robustly predicting outcomes and improving prognostic models to guide personalized therapies.
Browse by specialty
Open language-specific specialty feeds and department pages.